CHF-6366 is a dual-action chemical compound acting as a potent M3 muscarinic antagonist and beta2-adrenergic receptors agonist, with respective pK i values of 10.4 and 11.4. Additionally, it exhibits weak calcium channel inhibitory properties (IC 50 ~50 µM) and demonstrates the ability to inhibit bronchoconstriction in guinea pigs, making it a viable candidate for chronic obstructive pulmonary disease (COPD) research.
